1-7 of 7
Guiyuan Lei
Close
Sort by
Journal Articles

BCL2 Expression Identifies a Population with Unmet Medical Need in Previously Untreated (1L) Patients with DLBCL

Edith Szafer-Glusman, Franklin V. Peale, Jr., Guiyuan Lei, Anja Mottok, Pedro Farinha, Jill Ray, Thalia A. Farazi, Martin Kornacker, Mikkel Z. Oestergaard, Juan Liu, Randy D. Gascoyne, MD, Elizabeth Punnoose
Journal: Blood
Blood (2017) 130 (Supplement 1): 418.
https://doi.org/10.1182/blood.V130.Suppl_1.418.418
Published: 2017
Journal Articles

Prevalence and Prognostic Value of BCL2 and MYC Protein Expression within ABC and GCB Subtypes in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma: Analysis from the Phase III MAIN Study

Elizabeth Punnoose, Franklin V. Peale, Jr., Guiyuan Lei, Thomas Sandmann, Richard Bourgon, Edith Szafer-Glusman, An Do, Randy D. Gascoyne, Gilles A. Salles, MD PhD, John F. Seymour, MBBS, PhD, Marek Trneny, Laurie H. Sehn, F. Javier Munoz, Kirsten E. Mundt, PhD
Journal: Blood
Blood (2015) 126 (23): 3971.
https://doi.org/10.1182/blood.V126.23.3971.3971
Published: 2015
Journal Articles

Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study

Martin JS Dyer, Andrew P Grigg, MBBS FRACP FRCPA MD, Marcos González Díaz, MD PhD, Martin Dreyling, Simon Rule, MD, Guiyuan Lei, PhD, Elisabeth Wassner-Fritsch, PharmD, Günter Fingerle-Rowson, MDPhD, Paula V Marlton, MBBS
Journal: Blood
Blood (2014) 124 (21): 1743.
https://doi.org/10.1182/blood.V124.21.1743.1743
Published: 2014
Journal Articles

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

Clinical Trials & Observations
Guillaume Cartron, Sophie de Guibert, Marie-Sarah Dilhuydy, Franck Morschhauser, Veronique Leblond, Jehan Dupuis, Beatrice Mahe, Reda Bouabdallah, Guiyuan Lei, Michael Wenger, Elisabeth Wassner-Fritsch, Michael Hallek
Journal: Blood
Blood (2014) 124 (14): 2196–2202.
https://doi.org/10.1182/blood-2014-07-586610
Published: 2014
Includes: Supplemental data
Journal Articles

Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000)

Andrew Davies, MRCP, PhD, John Radford, MD, Guillaume Cartron, MD, PhD, Franck Morschhauser, MD, PhD, Gilles Andre Salles, MD, PhD, Robert Marcus, MB, FRCP, FRCPath, Michael K Wenger, MD, Guiyuan Lei, PhD, Elisabeth Wassner-Fritsch, PharmD, Umberto Vitolo, MD
Journal: Blood
Blood (2013) 122 (21): 1814.
https://doi.org/10.1182/blood.V122.21.1814.1814
Published: 2013
Journal Articles

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)

Clinical Trials & Observations
John Radford, Andrew Davies, Guillaume Cartron, Franck Morschhauser, Gilles Salles, Robert Marcus, Michael Wenger, Guiyuan Lei, Elisabeth Wassner-Fritsch, Umberto Vitolo
Journal: Blood
Blood (2013) 122 (7): 1137–1143.
https://doi.org/10.1182/blood-2013-01-481341
Published: 2013
Journal Articles

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Andrew Grigg, MBBS, FRACP, FRCPA, Marcos González, Martin Dreyling, Simon A. Rule, MD, Guiyuan Lei, Elisabeth Wassner-Fritsch, Michael K. Wenger, MD, Paula Marlton, MBBS, FRACP, FRCPA
Journal: Blood
Blood (2012) 120 (21): 3686.
https://doi.org/10.1182/blood.V120.21.3686.3686
Published: 2012